Story
European Stocks Rise as Tech Rebound Offsets AstraZeneca Plunge

Summary
European markets advanced Thursday, driven by a recovery in technology shares and easing geopolitical concerns, though gains were capped by a sharp decline in pharmaceutical giant AstraZeneca.
European equities rose in Thursday trading, led by a rebound in technology stocks as investor concerns over the conflict in the Middle East eased slightly. The pan-European STOXX 600 index was up 0.4% to 638.66 in morning trade, recovering from its largest single-day drop since March on Wednesday.
Tech Sector Leads Recovery
The technology sector was among the top performers, gaining 1.6% and reversing some of its recent underperformance this month. Chipmakers led the advance, with shares of Siltronic jumping 7.4%, Soitec adding 5.5%, and ASML rising 2.5%. The rally follows the sector's strongest quarterly performance since 2001, which was recorded in the second quarter.
Sentiment in the tech space was further supported by a report that China may grant its domestic AI firms limited access to high-end Nvidia chips, suggesting continued robust demand for AI infrastructure globally.
Geopolitical Tensions Ease
AdBroader market sentiment improved after U.S. President Donald Trump commented that he believed Iran wanted to "make a deal," according to Reuters. This helped calm investor nerves after the U.S. launched fresh strikes on Iran a day earlier. In response to the slightly de-escalated tone, crude oil prices edged lower, providing a tailwind for Europe's energy-importing economies.
Regionally, Spanish stocks outperformed with a 0.9% gain, rebounding from a three-week low. The move came after President Trump called Spain "very generous" in relation to its NATO contributions, easing trade-related fears from the previous session.
Corporate Movers
Limiting the broader market's advance, pharmaceutical heavyweight AstraZeneca saw its shares plunge 8%. The significant drop followed the company's announcement that its nerve disease drug Wainua, developed with Ionis, failed to meet the main goal of a late-stage trial focused on reducing cardiovascular deaths.